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Background
Tumor-derived autophagosomes, DRibbles, are novel can-
cer vaccines that have been shown to be effective in precli-
nical models of established tumors. We hypothesize that
DRibbles’ efficacy stems from their ability to present stabi-
lized tumor-derived short-lived proteins (SLiPs) and defec-
tive ribosomal products (DRiPs) that are normally not
processed and presented by professional antigen present-
ing cells (APCs). These SLiPs and DRiPs represent a
potential pool of tumor antigens against which the host is
not tolerant. The DPV-001 vaccine packages at least 40
putative cancer antigens, including twelve antigens from
the NCI’s list of prioritized antigens, multiple DAMPs and
agonist activity for TLR 2, 3, 4, 7 and 9 into stable double
membrane microvesicles. These microvesicles have surface
f-actin and spectrin that target DRibbles to CLEC9A+
APCs, the most effective APC at cross-priming immunity.
Methods and Results
Patients are vaccinated at 3-week intervals with a total of
7 doses. PBMCs and serum are collected at baseline and
at each vaccination. Immune monitoring panels are run
on peripheral whole blood to evaluate lymphocyte popu-
lations and their activation. PBMCs from the baseline
visit and week 12 are treated with DRibbles (vaccine and
control) to measure vaccine specific cytokine production.
Patient serum from the baseline visit and week 12 is ana-
lyzed for antibody response to >9000 human proteins
with ProtoArrays. We have identified multiple induced
and increased antibody responses, after vaccination
(n = 2 patients). UbiLT3 and UbiLT6 mutations were
compared to lung adenocarcinoma (LUAD) patient
mutations in the TCGA database (http://www.cbioportal.
org/public-portal/data_sets.jsp) to identify mutations
shared with the DPV-001 vaccine (UbiLT3 average 78.6;
UbiLT6 average 73.9 shared SNPs, excluding dbSNP
(common) variants). http://www.syfpeithi.de/bin/
MHCServer.dll/EpitopePrediction.htm was used to
find the ligation strength of reference and mutated
sequences on HLA types in order to predict potential
T cell epitopes.
Conclusions
The DPV-001 vaccine provides a source of broad-spec-
trum relevant antigens. Preliminary analyses of patients
receiving the DPV-001 vaccine show effects on T cells
and increased humoral antibody responses at 12 or 13
weeks. The DPV-001 vaccine contains mutations shared
with NSCLC patients in the TCGA database, including
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